UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications

Molecules (Basel, Switzerland), 2021-07, Vol.26 (15), p.4640

2021

Volltextzugriff (PDF)

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer

Molecules (Basel, Switzerland), 2023-05, Vol.28 (10), p.4022

2023

Volltextzugriff (PDF)

Orthogonal synthesis of a versatile building block for dual functionalization of targeting vectors

Open Chemistry, 2023-07, Vol.21 (1), p.293-9

2023

Volltextzugriff (PDF)

A Novel Luciferase-Based Reporter Gene Technology for Simultaneous Optical and Radionuclide Imaging of Cells

International journal of molecular sciences, 2024-08, Vol.25 (15), p.8206

2024

Volltextzugriff (PDF)

Radiochemical and Biological Evaluation of 3p- C -NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics

Pharmaceuticals (Basel, Switzerland), 2023-06, Vol.16 (6), p.882

2023

Volltextzugriff (PDF)

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors

Pharmaceuticals (Basel, Switzerland), 2022-09, Vol.15 (9), p.1155

2022

Volltextzugriff (PDF)

[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors

Pharmaceuticals (Basel, Switzerland), 2023-07, Vol.16 (7), p.985

2023

Volltextzugriff (PDF)

Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer

Pharmaceuticals (Basel, Switzerland), 2023-07, Vol.16 (8), p.1072

2023

Volltextzugriff (PDF)

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors

EJNMMI radiopharmacy and chemistry, 2024-05, Vol.9 (1), p.44-44, Article 44

2024

Volltextzugriff (PDF)

Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging

Cancers, 2023-04, Vol.15 (7), p.2161

2023

Volltextzugriff (PDF)

Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer

Pharmaceutics, 2022-01, Vol.14 (1), p.195

2022

Volltextzugriff (PDF)

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

EJNMMI radiopharmacy and chemistry, 2023-06, Vol.8 (1), p.13-13, Article 13

2023

Volltextzugriff (PDF)

Development of C-terminal modified long-acting DOTA-JR11 analogs for optimized treatment of NETs

Nuclear medicine and biology, 2023-11, Vol.126-127, p.108743, Article 108743

2023

Volltextzugriff (PDF)

Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S191

2022

Volltextzugriff (PDF)

P-259 - Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S191-S191

2022

Volltextzugriff (PDF)

Preclinical evaluation of ePSMA-DM1: a PSMA-targeting theranostic small molecule drug conjugate

Nuclear medicine and biology, 2023-11, Vol.126-127, p.108472, Article 108472

2023

Volltextzugriff (PDF)

A novel clickable MSAP agent for dual fluorescence/nuclear labeling of biovectors

Organic & biomolecular chemistry, 2020-08, Vol.18 (31), p.6134-6139

2020

Volltextzugriff (PDF)

P-260 - Albumin binders: a potential strategy for enhanced treatment of NETs using SSTR2 antagonists

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S191-S192

2022

Volltextzugriff (PDF)

Albumin binders: a potential strategy for enhanced treatment of NETs using SSTR2 antagonists

Nuclear medicine and biology, 2022-05, Vol.108-109, p.S191-S192

2022

Volltextzugriff (PDF)

Radiochemical and Biological Evaluation of 3p-IC/I-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics

Pharmaceuticals (Basel, Switzerland), 2023-06, Vol.16 (6)

2023

Volltextzugriff (PDF)

SP-083 - Development of versatile dual-modality imaging probes based on a GRPR antagonist for preoperative imaging and image-guided surgery of prostate cancer

Nuclear medicine and biology, 2021-05, Vol.96-97, p.S82-S82

2021

Volltextzugriff (PDF)

Development of versatile dual-modality imaging probes based on a GRPR antagonist for preoperative imaging and image-guided surgery of prostate cancer

Nuclear medicine and biology, 2021-05, Vol.96-97, p.S82

2021

Volltextzugriff (PDF)

Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors

Pharmaceuticals (Basel, Switzerland), 2023-07, Vol.16 (7)

2023

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer

Orthogonal synthesis of a versatile building block for dual functionalization of targeting vectors

A Novel Luciferase-Based Reporter Gene Technology for Simultaneous Optical and Radionuclide Imaging of Cells

Radiochemical and Biological Evaluation of 3p- C -NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors

[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors

Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors

Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging

Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

Development of C-terminal modified long-acting DOTA-JR11 analogs for optimized treatment of NETs

Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

P-259 - Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors

Preclinical evaluation of ePSMA-DM1: a PSMA-targeting theranostic small molecule drug conjugate

A novel clickable MSAP agent for dual fluorescence/nuclear labeling of biovectors

P-260 - Albumin binders: a potential strategy for enhanced treatment of NETs using SSTR2 antagonists

Albumin binders: a potential strategy for enhanced treatment of NETs using SSTR2 antagonists

Radiochemical and Biological Evaluation of 3p-IC/I-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics

SP-083 - Development of versatile dual-modality imaging probes based on a GRPR antagonist for preoperative imaging and image-guided surgery of prostate cancer

Development of versatile dual-modality imaging probes based on a GRPR antagonist for preoperative imaging and image-guided surgery of prostate cancer

Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors

Suchergebnisse filtern